Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Centocor briefing document for Ustekinumab, submitted to FDA
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
T cells become licensed in the lung to enter the central nervous system.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Demyelination affects temporal aspects of perception: An optic neuritis study.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pages